Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Maxwell

Showing results (181-190 of 200) with videos related to

Pageof 20
Sort By:
Medrxiv : the Preprint Server for Health Sciences|January 20, 2021
SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapyLova Sun, Sanjna Surya, Noah G Goodman, et al.
Cancer Research|July 18, 2020
A Rare <i>TP53</i> Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple CancersJacquelyn Powers, Emilia M Pinto, Thibaut Barnoud, et al.
European Urology|December 5, 2021
Inherited TP53 Variants and Risk of Prostate CancerKara N Maxwell, Heather H Cheng, Jacquelyn Powers, et al.
JCO Oncology Practice|June 16, 2021
SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed TherapyLova Sun, Sanjna Surya, Noah G Goodman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026Heather H Cheng, Veda N Giri, Michael Goggins, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 19, 2023
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024Mary B Daly, Tuya Pal, Kara N Maxwell, et al.
NPJ Precision Oncology|March 6, 2020
Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genesTyler Landrith, Bing Li, Ashley A Cass, et al.
Nature|March 4, 2026
Homologous recombination deficiency and hemizygosity drive resistance in breast cancerAnton Safonov, Minna Lee, David N Brown, et al.
Nature Medicine|May 21, 2021
CD8<sup>+</sup> T cells contribute to survival in patients with COVID-19 and hematologic cancerErin M Bange, Nicholas A Han, Paul Wileyto, et al.
American Journal of Human Genetics|October 31, 2025
BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotesSharon E Johnatty, Emma Tudini, Michael T Parsons, et al.
Pageof 20

Showing results (181-190 of 200) with videos related to

Sort By:
Pageof 20
Medrxiv : the Preprint Server for Health Sciences|January 20, 2021
SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapyLova Sun, Sanjna Surya, Noah G Goodman, et al.
Cancer Research|July 18, 2020
A Rare <i>TP53</i> Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple CancersJacquelyn Powers, Emilia M Pinto, Thibaut Barnoud, et al.
European Urology|December 5, 2021
Inherited TP53 Variants and Risk of Prostate CancerKara N Maxwell, Heather H Cheng, Jacquelyn Powers, et al.
JCO Oncology Practice|June 16, 2021
SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed TherapyLova Sun, Sanjna Surya, Noah G Goodman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026Heather H Cheng, Veda N Giri, Michael Goggins, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 19, 2023
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024Mary B Daly, Tuya Pal, Kara N Maxwell, et al.
NPJ Precision Oncology|March 6, 2020
Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genesTyler Landrith, Bing Li, Ashley A Cass, et al.
Nature|March 4, 2026
Homologous recombination deficiency and hemizygosity drive resistance in breast cancerAnton Safonov, Minna Lee, David N Brown, et al.
Nature Medicine|May 21, 2021
CD8<sup>+</sup> T cells contribute to survival in patients with COVID-19 and hematologic cancerErin M Bange, Nicholas A Han, Paul Wileyto, et al.
American Journal of Human Genetics|October 31, 2025
BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotesSharon E Johnatty, Emma Tudini, Michael T Parsons, et al.
Pageof 20